Aclarion, Inc., a healthcare technology company focused on chronic low back pain, has appointed Dan Isherwood as its UK Commercial Director. This marks Aclarion’s first dedicated commercial sales hire and highlights the company’s strategy to expand its market presence in the UK.
The UK has become Aclarion’s first market where physicians can order its Nociscan technology without the complexities of insurance payment issues. Nociscan is currently reimbursed by three out of the four largest private insurers in the UK, covering over 5.2 million patients.
“Dan’s hire represents a significant commercial milestone for the Company,” said Brent Ness, CEO of Aclarion. “The UK represents the first market where physicians can order Nociscan for their patients without navigating the friction around who is going to pay for the scan.”
Isherwood brings extensive experience in health technology and advanced imaging, previously holding key roles at major firms such as J&J MedTech and NuVasive. In his new role, he will be responsible for executing Aclarion’s strategies to strengthen physician and imaging center relationships and drive the adoption of Nociscan in the UK.
“I’m thrilled to join Aclarion at such an exciting time of growth,” Isherwood said. “I see tremendous potential for Nociscan to bring new, objective insights to clinicians managing patients with chronic low back pain.”
This development is notable as chronic low back pain affects an estimated 266 million people worldwide, and Aclarion’s Nociscan technology aims to enhance diagnosis and treatment options for these patients.
The primary source was GlobeNewswire.
